Leukemia, Myeloid, Acute
209
24
37
95
Key Insights
Highlights
Success Rate
72% trial completion
Published Results
53 trials with published results (25%)
Research Maturity
95 completed trials (45% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
17.7%
37 terminated out of 209 trials
72.0%
-14.6% vs benchmark
8%
16 trials in Phase 3/4
56%
53 of 95 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 95 completed trials
Clinical Trials (209)
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
Vyxeos for Induction of Low- or Intermediate-risk.
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia
Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML."
CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy